Our vision:
Bring individualized treatment decisions to all patients diagnosed with skin cancer
NeraCare is a leading developer of laboratory tests for personalized survival prediction of melanoma patients.
Our tests provide actionable, tumor-specific information for each individual patient. The information is used to improve patient care, most importantly to guide adjuvant therapy decision-making.
Through its partnerships with pharmaceutical companies and world leading investigators, NeraCare is at the forefront of designing cutting-edge clinical trials to help expand access to drugs for early stage patients.
NeraCare's first development is a quantitative RT-PCR-based assay – MELAGENIX
to help make individualised therapeutic decisions for stage II/III melanoma patients.
NeraCare's second development is an
immunohistochemistry-based test – immunoprint
– with focus on changing the treatment algorithm for patients diagnosed with early stage melanoma.
Further products for non-melanoma skin cancers are currently under development.
